Remission Rate of Rheumatoid Arthritis Patients and Associated Factors in Rheumatology Clinic, Khon Kaen Hospital
Keywords:
Rheumatoid arthritis, Remission, Achieving treatment target, FactorAbstract
Background and Objective: Rheumatoid arthritis (RA) is the most common of connective tissue disease and vary with prevalence in worldwide population. Remission rates still vary and several factors are involved. However, there was no previous systematic study in KhonKaen hospital. This research aimed to describe the remission rate and factors affecting treatment outcome of RA in KhonKaen hospital.
Methods: Cross-sectional study was performed on RA patients during January 2019–January 2020 who met American college of Rheumatology(ACR) 1987 revised criteria for the classification of RA or 2010 Rheumatoid Arthritis Classification Criteria for RA. We included patients older than 18 years-old who has been treated with ≥ 1 disease-modifying anti-rheumatic drugs (DMARDs) at least 1 year. Demographic data including characteristics of disease, laboratory and radiographic results, pattern and number of current DMARDs used, and disease activity score of 28 joints (DAS 28) were collected from RA database. Remission of disease define as achieving treatment target (DAS 28 < 3.2).
Results: A total of 320 RA patients recruited in this study was classified as female at the proportion of 263 (82.2%). Mean age of onset was 56.5 (SD17.6) years and disease duration was 71(IQ = 79) months. 41% (46 patients) of hypertension and 49.7% (159 patients) of secondary osteoarthritis were the common comorbidity diseases. The serology found positive rheumatoid factor (RF) of 45.3%. 42.2% had erosion before treatment. The combination of > 2 DMARDs (57.8%) was found to be the most common treatment pattern in which the main drug was methotrexate (92.8%). The median duration of prednisolone use was 15.5 (IQ = 26) months with mean amount of 2.5 (SD = 5) mg. For the outcome of treatment, 50 RA patients (15.6 %) were in remission (DAS 28 < 3.2), 70.3% of moderate (DAS 28 > 3.2 – 5.1) and 14.1% of high (DAS 28 > 5.1) disease activity. Factor associated with remission was < 2 current DMARDs (OR 2.08, 95% CI = 1.0-4.31) while factors associated non-remission were comorbidity of disease (OR 0.41, 95% CI = 0.19-0.92) and secondary osteoarthritis (OR 0.26, 95% CI = 0.10-.0.70).
Conclusion: The 50 cases (15.6%) of RA patients were in remission, defined as achieving treatment target (DAS 28 < 3.2). < 2 current DMARDs was a factor associated with remission whereas a comorbidity disease and secondary osteoarthritis were associated with non-remission among these patients.
References
Alamanos Y, Voulgari PV, Drosos AA. Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic review. Semin Arthritis Rheum 2006;36(3):182–8. doi: 10.1016/j.semarthrit.2006.08.006.
Lipsky PE. Rheumatoid Arthritis. In: Fauci A, et al. editors. Harrison’s Principles of Internal Medicine 17th ed. New York: McGraw Hill; 2008:2083-92.
Alamanos Y, Drosos AA. Epidemiology of adult rheumatoid arthritis. Autoimmun Rev 2005;4(3):130–6. doi: 10.1016/j.autrev.2004.09.002.
Chopra A, Abdel-Nasser A. Epidemiology of rheumatic musculoskeletal disorders in the developing world. Best Pract Res Clin Rheumatol 2008;22(4):583–604.
Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012;64(5):625–39. doi:10.1002/acr.21641.
Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73(3):492–509. doi:10.1136/annrheumdis-2013-204573.
Gotzsche PC, Johansen HK. Short-term low-dose corticosteroid vs placebo and nonsteriodal antiinflamatory drugs in rheumatoid arthritis. Cochrane Database Sys Rev 2004;2005(3):CD000189. doi: 10.1002/14651858.CD000189.pub2.
Smolen JS, Aletaha D, Bijlsma JWJ, Breedveld FC, Boumpas D, Burmester G, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69(4):631–7. doi:10.1136/ard.2009.123919.
Fransen J, van Riel PL. The disease activity score and the EULAR response criteria. Clin Exp Rheumatol 2005;23(5 Suppl 39):S93-9.
Fransen J, van Riel PL. The disease activity score and the EULAR response criteria Rheum. Dis Clin North Am 2009 ; 35(4):745-57, vii-viii. doi: 10.1016/j.rdc.2009.10.001. Review
Van Riel PL, The development of the disease activity score (DAS) and the disease activity score using 28 joint counts (DAS28). Clin Exp Rheumatol 2014;32(5 Suppl 85):S-65-74.
Medical practice guidelines for the diagnosis and treatment of rheumatoid arthritis, 2014. [Cited May 12, 2023]. https://www.thairheumatology.org/index.php/learning-center/for-physician/for-physician-3?view=article&id=73:1-29&catid=16.
Klarenbeek NB, Güler-Yüksel M, van der Kooij SM, Han KH, Ronday HK, Kerstens PJSM, et al. The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study. Ann Rheum Dis 2011;70(6):1039–46.
Katchamart W, Johnson S, Lin H-JL, Phumethum V, Salliot C, Bombardier C. Predictors for remission in rheumatoid arthritis patients: A systematic review. Arthritis Care Res (Hoboken) 2010 ;62(8):1128–43. doi:10.1002/acr.20188.
Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31(3):315–24. doi:10.1002/art.1780310302.
Kay J, Upchurch KS. ACR/EULAR 2010 rheumatoid arthritis classification criteria. Rheumatology (Oxford) 2012;51 (Suppl 6):vi5-9.
Tantiwong P, Nanagara R, Foocharoen C, Mahakkanukrauh A, Suwannaroj S. Disease modifying anti-rheumatic drugs [Dmards] used and treatment outcome of rheumatoid arthritis in Rheumatology clinic, Srinagarind Hospital. J Med Assoc Thai 2018;101(7):31-39.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Srinagarind Medical Journal
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
